Page 118 - Read Online

West et al. Rare Dis Orphan Drugs J 2024;3:22 https://dx.doi.org/10.20517/rdodj.2023.61 Page 33 of 34

Med 2016;375:545-55. DOI
162. Lenders M, Stappers F, Niemietz C, et al. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to
chaperone therapy. J Med Genet 2019;56:548-56. DOI
163. Rombach SM, Aerts JMFG, Poorthuis BJHM, et al. Long-term effect of antibodies against infused alpha-galactosidase a in Fabry
disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 2012;7:e47805. DOI PubMed PMC
164. Germain DP, Giugliani R, Hughes DA, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase
a activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis
2012;7:91. DOI PubMed PMC
165. Hughes DA, Bichet DG, Giugliani R, et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events,
including renal, cardiac and cerebrovascular outcomes. J Med Genet 2023;60:722-31. DOI PubMed PMC
166. Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry
disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1/2 clinical trial. J Inherit Metab
Dis 2019;42:534-44. DOI
167. Linhart A, Dostálová G, Nicholls K, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were
previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis 2023;18:332. DOI
PubMed PMC
168. Wallace EL, Goker-Alpan O, Wilcox WR, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with
Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet
2024;61:520-30. DOI PubMed PMC
169. Deegan PB. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis 2012;35:227-
43. DOI PubMed
170. Bodensteiner D, Scott CR, Sims KB, Shepherd GM, Cintron RD, Germain DP. Successful reinstitution of agalsidase beta therapy in
Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med 2008;10:353-8. DOI
PubMed
171. Talreja N, Butt A, Del Valle RL, Fox RW, Lockey RF. Successful desensitization to agalsidase beta after anaphylaxis. Ann Allergy
Asthma Immunol 2014;112:71-2. DOI PubMed
172. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies
toward agalsidase alpha and beta. Kidney Int 2004;66:1589-95. DOI PubMed
173. Lenders M, Neußer LP, Rudnicki M, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody
titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol 2018;29:2879-89. DOI PubMed PMC
174. van der Veen SJ, Vlietstra WJ, van Dussen L, et al. Predicting the development of anti-drug antibodies against recombinant alpha-
galactosidase a in male patients with classical Fabry disease. Int J Mol Sci 2020;21:5784. DOI PubMed PMC
175. Lenders M, Brand E. Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease. Front Immunol
2022;13:1024963. DOI PubMed PMC
176. Curelaru S, Desai AK, Fink D, Zehavi Y, Kishnani PS, Spiegel R. A favorable outcome in an infantile-onset Pompe patient with
cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted
immunomodulation. Mol Genet Metab Rep 2022;32:100893. DOI PubMed PMC
177. Mhanni AA, Auray-Blais C, Boutin M, et al. Therapeutic challenges in two adolescent male patients with Fabry disease and high
antibody titres. Mol Genet Metab Rep 2020;24:100618. DOI PubMed PMC
178. Hughes D, Gonzalez D, Maegawa G, et al. Long-term safety and efficacy of pegunigalsidase alfa: a multicenter 6-year study in adult
patients with Fabry disease. Genet Med 2023;25:100968. DOI
179. FDA. 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf [Last accessed on 11 Jul
2024].
180. Lenders M, Pollmann S, Terlinden M, Brand E. Pre-existing anti-drug antibodies in Fabry disease show less affinity for
pegunigalsidase alfa. Mol Ther Methods Clin Dev 2022;26:323-30. DOI PubMed PMC
181. Guérard N, Oder D, Nordbeck P, et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and
pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther 2018;103:703-11. DOI
182. Deegan PB, Goker-Alpan O, Geberhiwot T, et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment
over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. Mol Genet Metab
2023;138:106963. DOI PubMed PMC
183. Khan A, Barber DL, Huang J, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun 2021;12:1178. DOI PubMed
PMC
184. Hopkin RJ, Ganesh J, Bernat J, et al. Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: updated results
from an ongoing phase 1/2 study (STAAR). Mol Genet Metab 2024;141:107884. DOI
185. Schiffmann R, Goker-Alpan O, Vockley J, et al. Cardiac effects of 4D-310 in adults with Fabry disease in a phase 1/2 clinical trial:
Functional, quality of life, and imaging endpoints in patients with 12 months of follow up. Mol Genet Metab 2023;138:107306. DOI
186. Lek A, Wong B, Keeler A, et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne’s muscular dystrophy. N
Engl J Med 2023;389:1203-10. DOI
187. Nagree MS, Felizardo TC, Faber ML, et al. Autologous, lentivirus-modified, T-rapa cell “micropharmacies” for lysosomal storage